The Cardiovascular Research Foundation (CRF) is pleased to announce that Puzzle Medical Devices Inc. has won the TCT 2022 Shark Tank Innovation Competition for its novel circulatory support device that is implanted percutaneously in the abdominal aorta. The competition took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in interventional cardiovascular medicine, September 16-19 in Boston. The winner was also presented with the Jon DeHaan Foundation Award for Innovation in Cardiology.
UCSF Health’s Heart and Vascular Center is welcoming Sammy Elmariah, MD, MPH, FACC, FAHA, FSCAI, as chief of its division of Interventional Cardiology and medical director of the division’s cardiac catheterization lab. Elmariah is a recognized expert in structural heart disease interventions and catheter-based valve therapies.
Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the PASCAL transcatheter valve repair system was non-inferior compared with MitraClip in patients with significant symptomatic DMR who are not eligible for mitral valve surgery.
Findings from the CLASP IID trial were reported today at TCT 2022, the 34th annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.
An analysis from the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) TVT Registry found that most patients with severe mitral regurgitation (MR) and cardiogenic shock (CS) who underwent mitral transcatheter edge-to-edge repair (TEER) in the United States achieved successful MR reduction, and that successful repair was associated with lower mortality and heart failure (HF) hospitalizations at one year post-procedure compared with unsuccessful repair.
A study published today in the New England Journal of Medicine (NEJM) found that among patients with aortic stenosis undergoing transfemoral TAVR, the use of a debris capturing device called cerebral embolic protection reduced the risk of disabling stroke from 1.3% to 0.5%.
Mount Sinai Heart leader will be recognized for his exceptional career achievements at the 34th annual conference.
After a rare disease caused organ failure, UC San Diego Heath transplant teams performed a heart, liver and kidney transplant on a patient. The surgery is a first for UC San Diego Health and a first in the nation to use three organs from a donor after circulatory death.
Researchers at the Georgia Institute of Technology and clinicians at Emory University School of Medicine are bringing a new understanding to these complicated conditions with the first high-resolution visualizations of stable spiral waves in human ventricles.
A clinical trial of patients with COVID-19 led by investigators at the TIMI Study Group at Brigham and Women’s Hospital and the Critical Care Cardiology Trials Network (CCCTN) has found that full-dose anticoagulation lowers the risk of blood clotting complications compared with standard-dose prophylactic anticoagulation.
A new type of extravascular implantable cardioverter-defibrillator (ICD) using a lead (thin wire) placed behind the sternum met safety and effectiveness goals for participants in a premarket global clinical study. The device effectively terminated acute and chronic life-threatening ventricular arrhythmias. The findings were presented during a late-breaking session at the European Society of Cardiology Congress and were simultaneously published in The New England Journal of Medicine.
The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that the program is now available for the TCT MedTech Innovation Forum. The summit will be held on the first day of TCT, the annual scientific symposium of CRF, on Friday, September 16. TCT will take place September 16-19, 2022, in Boston, Massachusetts, at the Boston Convention and Exhibition Center.
Twenty-six Children’s Hospital Los Angeles physicians, nurses and leaders will serve as presenters at the 25th Annual Cardiology 2022 Conference, themed “The New Normal: Transformation in Pediatric & Congenital Heart Disease.”
Pascack Valley Medical Group announced that Mohammed Gibreal, M.D. has joined the practice’s cardiology group. As a noninvasive cardiologist practicing in community hospitals and tertiary care medical centers, Dr. Gibreal has vast experience delivering care in inpatient and outpatient settings.
Two leaders in cardiovascular disease science, research and education, the American Heart Association (Association) and the Cardiovascular Research Foundation (CRF), are joining forces to strengthen and expand educational opportunities focused on advancing the latest research in cardiovascular disease and interventional therapies. The new alliance to produce joint education programs begins immediately with the organizations’ annual scientific meetings this fall. The Association will present educational programming from its annual Scientific Sessions at TCT, and CRF will deliver educational programming from its annual scientific symposium Transcatheter Cardiovascular Therapeutics (TCT) at the Association’s Scientific Sessions, beginning with TCT 2022, September 16-19 in Boston, and the Association’s Scientific Sessions 2022, November 5-7 in Chicago, respectively.
Heart failure may seem like a disease of advanced age, but it can develop at any time in life. And, in many cases, it can be prevented or treated. In this expert alert, Gosia Wamil, M.D., Ph.D., a cardiologist at Mayo Clinic Healthcare in London, explains risk factors, symptoms that people may not be aware of and how heart failure is treated.
A pilot program at The Brookdale University Hospital and Medical Center, Brooklyn, New York — designed to help patients manage heart failure after hospital discharge — quickly improved patient adherence to their medication and treatment plan, and resulted in fewer readmissions among the initial 47 patients.
MedStar Washington Hospital Center has again achieved national ranking for Cardiology & Heart Surgery in the 2022-23 U.S. News & World Report “Best Hospitals” rankings. It moved up to No. 28, from No. 30 last year. It is the only nationally recognized heart program of its kind in the Washington metropolitan area. MedStar Washington also earned “high performing” ratings in cancer, gastroenterology & GI surgery, Urology, and in 12 common procedures and conditions.
Hackensack Meridian Jersey Shore University Medical Center’s Chief of Cardiology Brett Sealove, M.D., FACC, RPVI, is available for interview or comment about a new study published in the American Heart Association Journal on July 25, 2022, regarding people who often…
Patients with a specific form of age-related macular degeneration (AMD), a leading cause of blindness in the United States, are at significant risk for cardiovascular disease and stroke, according to new research from New York Eye and Ear Infirmary of Mount Sinai.
Adults with abnormal heart metabolism are up to three times more likely to experience life-threatening arrhythmias (an irregular heart rhythm), and MRI techniques could be used to detect the condition and predict future sudden cardiac death (SCD), according to a small, but rigorous study led by Johns Hopkins Medicine researchers.
UC San Diego researchers report significant decrease in national cases of Kawasaki disease during COVID-19 pandemic; findings hint at origins of disease.
Duke Children’s Hospital & Health Center continues to rank as the No. 1 children’s hospital in North Carolina by U.S. News & World Report, with nine pediatric specialties ranked among the best in the nation.
U.S. News has again ranked CHLA as the top children’s hospital in California and in the survey’s Pacific U.S. region—which encompasses Alaska, California, Hawaii, Oregon and Washington. CHLA also made the publication’s annual Honor Roll of Best Children’s Hospitals for the 14th consecutive year—every year since its inception—finishing No. 8 in the United States in this showcase of the nation’s leading destinations for pediatric medical care.
U.S. News ha clasificado de nuevo al CHLA como el mejor hospital pediátrico en el estado de California y en el Pacífico de los Estados Unidos, una región que abarca los estados de Alaska, California, Hawái, Oregón y Washington. El CHLA también se encuentra en el cuadro de honor anual de la publicación de los mejores hospitales para niños por decimocuarto año consecutivo, todos los años desde el inicio de la clasificación, en donde obtuvo el puesto n. 8 en los Estados Unidos en esta muestra de los principales destinos del país para la atención médica pediátrica.
A retrospective review of more than 24,000 patients who underwent an EKG at Mayo Clinic finds that nearly one-quarter of the patients had mitral annulus calcification, a chronic degeneration of tissue at the base of the heart’s mitral valve.
Sean Swearingen, MD, a sports cardiologist at RUSH, outlines ways to target your workout for maximum benefit and minimum strain..
Tips from a clinical dietitian for keeping babies healthy when formula is in short supply. It’s no secret the COVID pandemic has brought with it a spate of supply chain challenges. The latest product in crisis: infant and child formula.The shortage has affected nearly all types of formulas, hitting those who require special formulas the hardest: children with milk allergies, developmental disabilities and special needs, among other conditions.
Eating low glycaemic index foods promotes a healthier body shape in patients with coronary artery disease, according to a study presented at ACNAP-EuroHeartCare Congress 2022, a scientific congress of the European Society of Cardiology (ESC).1
DETROIT (May 17, 2022) – For the third straight year, Henry Ford Hospital interventional cardiologist Khaldoon Alaswad, M.D. will perform a live heart procedure as part of an international interactive medical education event, with proceeds benefiting hospitals in Ukraine.Dr. Alaswad, director of the cardiac catheterization lab, will perform an advanced heart procedure known as chronic total occlusion percutaneous coronary intervention, as part of CTO LIVE AID 2022, a livestreamed event to provide invaluable training to cardiologists around the world.
Herbal supplements may be natural, but that does not mean they are always safe.
COVID-19, MIS-C and KD all share a similar underlying mechanism involving the over-activation of particular inflammatory pathways, UC San Diego study shows. Findings support novel drug targets for MIS-C.
The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 12 studies as Late-Breaking Clinical Science and Featured Clinical Research. An annual meeting covering cutting-edge research and techniques for structural heart interventions, TVT will take place June 8-10, 2022, at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.
A new report by a team of cardiologists from the Heart & Vascular Hospital, Hackensack Meridian Hackensack University Medical Center that compares the hemodynamics of cardiac shock in patients with COVID-19 during the first versus the second wave of the COVID-19 pandemic was published recently in JACC: Journal of the American College of Cardiology.
The program for TVT 2022: The Structural Heart Summit is now available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions and will take place June 8-10, 2022 at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.
Media registration is now open for TCT 2022 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will be held September 16-19, 2022, in Boston, Massachusetts at the Boston Convention and Exhibition Center.
UC San Diego researchers describe the underlying signaling pathway that results in pulmonary arterial hypertension and a novel monoclonal antibody therapy that blocks the abnormal blood vessel formation characterizing the disease.
Ochsner Health created a Transitional Care Clinic to reduce readmissions and, ultimately, improve the quality of life and survival of patients with congestive heart failure.
Single-lead ECG tracings from an Apple Watch interpreted by an artificial intelligence (AI) algorithm developed at Mayo Clinic effectively identified patients with a weak heart pump.
Cardiovascular medicine is ranked among the lowest in terms of female representation in the United States, and cardiac electrophysiology is a predominantly male field.
Study Used Wearable Tech to Foster Activity in High-Risk, Diverse Populations
Findings from a new Cleveland Clinic-led phase 1 trial show that an experimental “gene silencing” therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%.
Findings from the “APOLLO Trial: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial” were presented today during a late-breaking science session at American College of Cardiology’s 71st Annual Scientific Session and simultaneously published online in the Journal of the American Medical Association.
Findings from a Cleveland Clinic-led clinical trial showed that the use of an experimental drug in severely symptomatic, hypertrophic cardiomyopathy patients significantly reduced the need for invasive procedures.
SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure (LAAC) as evaluated by 45-day cardiac computed tomography angiography (CCTA). The study showed that the two devices achieve a similar rate of LAA occlusion at 45 days but through different mechanism. Furthermore, Amulet as compared with Watchman FLX was associated with higher procedural complications but similar clinical outcomes at 45-days.
Results from the largest randomized trial available comparing different closure device strategies following transcatheter aortic valve replacement (TAVR) found that a plug-based vascular closure technique had a shorter time to hemostasis but a higher rate of access-site or access-related vascular complications.
An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk, found that despite higher procedural costs, at 2-year follow-up, quality-adjusted life expectancy was greater and total costs were lower with TAVR; as a result, at 2-years, TAVR was cost-effective for these patients.
Results from SUGAR, a randomized, controlled, multicenter trial conducted exclusively in patients with diabetes mellitus (DM) and with minimum exclusion criteria, found that amphilimus-eluting stents (AES) were superior to zotarolimus-eluting stents (ZES) with regard to target lesion and target vessel failure composite outcomes at one year.
The primary results of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 trial found that percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) did not meet noninferiority for one-year adverse events compared to coronary artery bypass grafting (CABG) in patients with three-vessel coronary artery disease. Patients with a low SYNTAX score (which measures the complexity of coronary artery disease) had less incidence of adverse events compared to those with intermediate or high SYNTAX scores, and in this cohort of patients PCI performed more favorably.
Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound renal denervation (RDN) to a sham procedure for treatment-resistant hypertension (HTN) found that the addition of a pharmacologic intervention led to further blood pressure reductions after RDN with a smaller increase in additional medications prescribed and less use of diuretics.
The FAVOR III China trial found that lesion selection for percutaneous coronary intervention (PCI) using the non-invasively assessed physiologic measurement quantitative flow ratio (QFR) improved outcomes for PCI compared with a standard angiography-guided strategy.
New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality or stroke between patients at intermediate surgical risk who had transcatheter aortic valve replacement (TAVR) or surgery. Although there were initially more reinterventions after TAVR, the rates were similar after two years and key clinical endpoints were also similar.